New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2013
07:39 EDTARIAARIAD reports Q4 EPS (36c), consensus (35c)
Reports Q4 revenue $74K, consensus $500K.
News For ARIA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
07:38 EDTARIAARIAD appoints DesRosier as Chief Legal and Administrative Officer
Subscribe for More Information
January 20, 2015
07:36 EDTARIAARIAD says EC endorses final opinion adopted by CHMP on Iclusig
Subscribe for More Information
January 14, 2015
07:20 EDTARIAARIAD sees product revenues reaching over $400M in 2018
For 2014, sees product and license revenue at $100M, R&D expenses $120M. For 2015, plans to accelerate Iclusig sales in U.S. and Europe, initiate key Iclusig trials, secure broad partnership for brigatinib, file for Iclusig approval in Japan with Otsuka, file IND for new development candidate AP32788. Comments from slides that will be presented at the JP Morgan Healthcare Conference.
January 13, 2015
07:40 EDTARIAARIAD reports net sales of Iclusig of approx. $55M for year ended Dec. 31
Subscribe for More Information
07:39 EDTARIAARIAD announces key strategic objectives for 2015
ARIAD Pharmaceuticals announced its key strategic objectives for 2015, details of which will be presented at the 33rd Annual J.P. Morgan Healthcare Conference on January 14, 2015 in San Francisco, California. These objectives are focused on expanded commercial, research and development, and new business development initiatives that together are expected to lead ARIAD to sustained profitability beginning in 2018 without the need for additional equity capital to fund its operations. ARIAD management will provide detail on its corporate strategy for the next several years. This new focus includes: Expanding the global commercial opportunity for Iclusig through a Japan/Asia partnership with Otsuka Pharmaceutical Co., Ltd., and additional regional distributorships, Leveraging its existing commercial infrastructure and investment, particularly in Europe, Securing a broad co-development and co-commercialization partnership for brigatinib, or AP26113, that will accelerate the study of brigatinib in earlier lines of treatment, Investing in three randomized clinical trials to evaluate Iclusig in earlier lines of treatment and potentially to expand its addressable market, Advancing its new development candidate, AP32788, into the clinic, and Achieving sustained profitability in 2018 by reaching global product revenue of more than $400M. Three key Iclusig clinical trials will begin in 2015 including a randomized, Phase 3 trial in patients with chronic-phase CML who have experienced failure after imatinib therapy. This second-line, global trial will evaluate two doses of Iclusig vs. the standard dose of nilotinib. The primary endpoint of the trial will be major molecular response by 12 months. The trial is expected to open to patient enrollment in the second half of 2015 and will be integral to potentially expanding Iclusig into earlier lines of treatment. We expect that approximately 500 patients will be enrolled in this trial. ARIAD says "In a major strategic shift for ARIAD, we expect to secure a broad partnership in 2015 to co-develop and co-commercialize brigatinib. In doing so, we will continue to leverage our existing infrastructure and capabilities, allowing us to accelerate the start of a randomized, first-line trial of brigatinib vs. crizotinib. A partnership will also provide for the exploration of new combination therapies in lung cancer that include brigatinib potentially with other approved and unapproved medicines." The company comments, "We expect to achieve profitability in 2018 through revenue growth and strategic partnerships over the next three years. This includes Iclusig revenue growth in the U.S. and in Europe, as well as Iclusig revenue from Japan and new geographies. We also anticipate increased cash flow from brigatinib revenue and partnership payments during this time period. We expect approval of Iclusig in Canada and Israel in 2015 and in Japan in 2016."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use